Related Experiment Video
Updated: Nov 6, 2025
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
504
Cellular Therapies for Mantle Cell Lymphoma.
Farah Yassine1, Jose Sandoval-Sus2, Ernesto Ayala1
1Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, Florida.
Transplantation and Cellular Therapy
|May 9, 2021
Summary
Mantle cell lymphoma (MCL) treatment advances include hematopoietic cell transplant (HCT) and chimeric antigen receptor T cell (CAR T) therapy. This review details cellular therapies and offers a treatment algorithm for MCL.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Mantle cell lymphoma (MCL) is a B cell non-Hodgkin lymphoma with varied clinical presentations.
- Current front-line consolidation for eligible patients involves autologous hematopoietic cell transplant (HCT) followed by rituximab maintenance.
- Allogeneic HCT is considered for younger, fit patients with high-risk disease or after autologous HCT failure.
Purpose of the Study:
- To review available cellular therapies for MCL.
- To present a treatment algorithm integrating HCT and CAR T cell therapies for MCL management.
Main Methods:
- Comprehensive literature review of cellular therapies for MCL.
- Development of a treatment algorithm based on current evidence.
Main Results:
- Autologous HCT is a standard front-line consolidation therapy for responsive MCL patients.
- Allogeneic HCT serves as an option for specific patient groups, including relapsed cases.
- Chimeric antigen receptor T cell (CAR T) therapy, exemplified by brexucabtagene autoleucel, is a significant advancement for relapsed/refractory MCL.
Conclusions:
- Cellular therapies, including autologous and allogeneic HCT and CAR T therapy, represent key treatment modalities for MCL.
- The proposed treatment algorithm aims to guide the optimal integration of these advanced therapies in MCL patient care.
Keywords:
Allogeneic hematopoietic cell transplantationAutologous hematopoietic cell transplantationChimeric antigen receptorMantle cell lymphomaT cell therapyMore Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:21Stem Cell Therapy for Tissue Regeneration
4.3K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.3K
01:27Tumor Immunotherapy
804
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
804
02:50Combination Therapies and Personalized Medicine
5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
01:22Bone Marrow Sampling and Transplants
616
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
616
01:15Differentiation of Common Myeloid Progenitor Cells
3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K